For a patient with metastatic colon cancer who tested positive for MSI (i.e. MLH1 hypermethylation etc) and BRAF mutation, what would be your preferred choice in the second line setting?
Would you choose to use IO or BRAF directed therapy based on BEACON? Or would you continue to use cytotoxic chemotherapy?
Do you consider MLH1/PMS2 hypermethylation MMR/def...
Especially when they turn out to be BRAF Mutant?
Yes, those patients are considered MMR-D.